KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to -$448.3 million.

  • Alnylam Pharmaceuticals' Cash from Financing Activities fell 53632.72% to -$448.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.5 million, marking a year-over-year decrease of 20566.16%. This contributed to the annual value of $294.2 million for FY2024, which is 7089.25% up from last year.
  • Alnylam Pharmaceuticals' Cash from Financing Activities amounted to -$448.3 million in Q3 2025, which was down 53632.72% from $53.8 million recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Cash from Financing Activities registered a high of $573.8 million during Q3 2021, and its lowest value of -$448.3 million during Q3 2025.
  • In the last 5 years, Alnylam Pharmaceuticals' Cash from Financing Activities had a median value of $51.2 million in 2021 and averaged $94.1 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Cash from Financing Activities skyrocketed by 158049.61% in 2021, and later tumbled by 53632.72% in 2025.
  • Alnylam Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $292.3 million in 2021, then tumbled by 78.3% to $63.4 million in 2022, then tumbled by 38.16% to $39.2 million in 2023, then fell by 20.98% to $31.0 million in 2024, then crashed by 1546.42% to -$448.3 million in 2025.
  • Its Cash from Financing Activities stands at -$448.3 million for Q3 2025, versus $53.8 million for Q2 2025 and $44.1 million for Q1 2025.